Efficacy And Clinical DevelopmentRezpeg achieved statistical significance on the primary endpoint and all key secondary endpoints, indicating its strong therapeutic potential.
Financial PerformanceFor 2Q25, the company reported revenue of $11.2M and a net loss of $2.95 per share, compared to the consensus estimated revenue of $9.5M and a net loss of $3.03.
Patient-Reported OutcomesPatient-reported outcomes demonstrated significant benefits for rezpeg, including improvements in quality of life, disease control, sleep, and pain reduction.